Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider... Show more
IQV saw its Momentum Indicator move above the 0 level on November 11, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned positive. In of the 74 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on November 24, 2025. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 238 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for IQV moved out of overbought territory on November 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IQV broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.238) is normal, around the industry mean (12.615). P/E Ratio (31.036) is within average values for comparable stocks, (138.269). Projected Growth (PEG Ratio) (0.957) is also within normal values, averaging (1.935). IQV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (2.493) is also within normal values, averaging (11.056).
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QTOC | 33.87 | -0.06 | -0.17% |
| Innovator Growth Accelertd Pls ETF™ Oct | |||
| FFLG | 29.85 | -0.13 | -0.43% |
| Fidelity Fundamental Large Cap Gr ETF | |||
| DEW | 61.07 | -0.36 | -0.59% |
| WisdomTree Global High Dividend ETF | |||
| SHLD | 60.74 | -1.66 | -2.66% |
| Global X Defense Tech ETF | |||
| RGTU | 21.77 | -3.48 | -13.78% |
| Tradr 2X Long RGTI Daily ETF | |||
A.I.dvisor indicates that over the last year, IQV has been loosely correlated with MEDP. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IQV jumps, then MEDP could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | -0.67% | ||
| MEDP - IQV | 57% Loosely correlated | -0.79% | ||
| ICLR - IQV | 56% Loosely correlated | -2.82% | ||
| SYK - IQV | 54% Loosely correlated | +0.31% | ||
| ALC - IQV | 51% Loosely correlated | -1.40% | ||
| TMO - IQV | 51% Loosely correlated | -0.96% | ||
More | ||||